Alan Faraj
Visiting researcher at Department of Pharmacy; Pharmacometrics
- E-mail:
- alan.faraj@uu.se
- Visiting address:
- Biomedicinskt Centrum BMC, Husargatan 3
- Postal address:
- Box 580
751 23 UPPSALA
Download contact information for Alan Faraj at Department of Pharmacy; Pharmacometrics
Short presentation
I am a guest researcher in the pharmacometrics group and my main interest is within the scope and usage of modeling & simulation through pharmacometric methodology to ensure informed decision making in early and late clinical development of drugs. In particular, I am passionate about dose selection to maximize the probability of trial success.
Besides working at the university, I am a MIDD consultant aiding support in clinical development programs at Novo Nordisk.

Publications
Recent publications
-
A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
Part of PLoS biology, 2024
- DOI for A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
- Download full text (pdf) of A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
-
Part of Clinical Pharmacology and Therapeutics, p. 498-505, 2024
- DOI for Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
- Download full text (pdf) of Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
-
2024
-
Part of CPT, p. 977-987, 2023
- DOI for Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
- Download full text (pdf) of Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
-
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study
Part of Annals of the American Thoracic Society, p. 1822-1825, 2023
All publications
Articles in journal
-
A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
Part of PLoS biology, 2024
- DOI for A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
- Download full text (pdf) of A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
-
Part of Clinical Pharmacology and Therapeutics, p. 498-505, 2024
- DOI for Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
- Download full text (pdf) of Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
-
Part of CPT, p. 977-987, 2023
- DOI for Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
- Download full text (pdf) of Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
-
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study
Part of Annals of the American Thoracic Society, p. 1822-1825, 2023
-
Part of Frontiers in Pharmacology, 2023
- DOI for Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
- Download full text (pdf) of Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
-
Part of Advances in Therapy, p. 3739-3750, 2023
- DOI for Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
- Download full text (pdf) of Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
-
Part of CPT, p. 1628-1637, 2022
- DOI for Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
- Download full text (pdf) of Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
-
Part of American Journal of Respiratory and Critical Care Medicine, p. 1228-1235, 2022
-
Part of Scientific Reports, 2020
- DOI for Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions
- Download full text (pdf) of Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions
-
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 421-430, 2020
- DOI for A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis.
- Download full text (pdf) of A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis.
-
Part of Antimicrobial Agents and Chemotherapy, 2020
- DOI for Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
- Download full text (pdf) of Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients